Chronic Lymphocytic Leukemia CLL Prognostic Panel Test
Comprehensive Prognostic Assessment for CLL Management
The Chronic Lymphocytic Leukemia CLL Prognostic Panel Test represents a cutting-edge molecular diagnostic approach specifically designed to evaluate disease progression risk and guide personalized treatment strategies for patients diagnosed with chronic lymphocytic leukemia. This comprehensive panel integrates multiple advanced testing methodologies to provide hematologists and oncologists with critical prognostic information essential for developing targeted therapeutic interventions and predicting disease outcomes.
What This Advanced Panel Measures
Our CLL Prognostic Panel employs sophisticated molecular techniques to analyze key biomarkers that significantly influence disease behavior and treatment response:
- ZAP-70 Expression: Evaluates tyrosine kinase activity associated with aggressive disease progression
- CD38 Status: Assesses surface marker expression linked to poor prognosis
- CD49d Analysis: Measures integrin expression affecting lymphocyte migration and survival
- IGVH Mutation Profile: Determines immunoglobulin variable region mutation status, a critical prognostic indicator
- Chromosomal Abnormalities: Detects specific deletions including del11q23(ATM), del17p13.1(TP53), del13q14.3, del13q34, and Trisomy 12
Who Should Consider This Test
This prognostic panel is particularly valuable for patients experiencing:
- Newly diagnosed chronic lymphocytic leukemia requiring risk stratification
- Unexplained lymphocytosis with suspected CLL progression
- Enlarged lymph nodes, spleen, or liver associated with CLL
- Fatigue, night sweats, or unexplained weight loss in CLL patients
- Planning for treatment initiation or considering watchful waiting strategies
- Monitoring disease progression in established CLL cases
Significant Benefits of CLL Prognostic Testing
Undergoing comprehensive prognostic assessment provides numerous advantages for both patients and healthcare providers:
- Personalized Treatment Planning: Enables tailored therapeutic approaches based on individual risk profiles
- Accurate Risk Stratification: Identifies patients requiring immediate intervention versus those suitable for observation
- Predictive Treatment Response: Helps anticipate how patients may respond to specific chemotherapy or targeted therapies
- Early Intervention Guidance: Supports timely treatment decisions before disease progression occurs
- Improved Clinical Outcomes: Facilitates evidence-based management strategies leading to better survival rates
Understanding Your Test Results
Your comprehensive CLL prognostic report will provide detailed insights into your disease characteristics:
- Favorable Prognostic Markers: Unmutated IGVH, absence of ZAP-70 expression, and normal chromosomal findings typically indicate slower disease progression
- High-Risk Indicators: Presence of del17p13.1(TP53), del11q23(ATM), or high CD38 expression suggests aggressive disease requiring immediate intervention
- Intermediate Risk Factors: Trisomy 12 or specific deletion patterns may indicate moderate disease aggressiveness
- Treatment Implications: Results guide selection between chemotherapy, immunotherapy, targeted therapies, or clinical trial participation
All results should be thoroughly discussed with your hematologist or oncologist to develop an appropriate management plan tailored to your specific prognostic profile.
Test Pricing and Availability
| Test Component | Regular Price | Discount Price |
|---|---|---|
| Chronic Lymphocytic Leukemia CLL Prognostic Panel Test | $750 USD | $576 USD |
Nationwide Testing Accessibility
General Genetics Corporation maintains comprehensive testing facilities across major metropolitan areas throughout the United States, including New York, Los Angeles, Chicago, Houston, Phoenix, and Philadelphia. Our state-of-the-art molecular diagnostics laboratories ensure rapid turnaround times with samples processed by Monday 9 AM and reports delivered the following Monday.
Take Control of Your CLL Management Today
Don’t leave your chronic lymphocytic leukemia management to chance. Our comprehensive prognostic panel provides the critical information needed to make informed treatment decisions and optimize your clinical outcomes. With advanced molecular diagnostics and expert interpretation, you can approach your CLL journey with confidence and clarity.
Call +1(267) 388-9828 now to schedule your Chronic Lymphocytic Leukemia CLL Prognostic Panel Test and take the first step toward personalized, evidence-based CLL management.
